Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2015

View Archived Issues

Enumeral anti-PD-1 and anti-TIM-3 antibodies may potentiate antitumor immune responses

NIAID awards SRI International contract to develop treatments for radiation exposure

Progress made by the Center for Infectious Disease Research's partnership with GSK on TB

Johnson & Johnson Innovation announces new collaborations

Ultragenyx reports interim data from phase II study of UX-007

Sunshine Lake Pharma and Calitor Sciences present kinase inhibitors

Ignyta and Cancer Research Technology divulge PKC iota inhibitors

OPKO subsidiary and Vanderbilt University School of Medicine collaborate on genomics

Once-weekly growth hormone NN-8640 shows promise in phase I trial

Lilly and ImaginAb enter into preclinical research collaboration in immuno-oncology

Karolinska Institutet coordinates study of stem cells in unborn babies with osteogenesis imperfecta

MSD submits NDA for desloratadine in Japan

First-in-human results presented for personalized immunotherapy

Enzyme replacement therapy developed for MPS IIID

Roche patents autotaxin inhibitors

ViroCarb divulges HIV viral entry inhibitors

Transition Therapeutics reports data from phase II/III trial of ELND-005

Nordic Nanovector revises clinical development plan for Betalutin

New compound targets P2X purinoceptor 7 in experimental uveitis

EMA adopts positive opinion on new orphan designations for KTE-C19

Topical therapy Tendoncel shows promise in phase II study of tendon injury

Eisai and Ajinomoto sign agreement to form gastrointestinal specialty company

FDA issues complete response letter for saxagliptin/dapagliflozin NDA

Loxo Oncology initiates phase II basket trial of LOXO-101 for solid tumors with TRK fusions

MacroGenics provides update on several DART programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...